Mike Hollan

Veltre will develop the company’s media and digital strategy.

Alexander continues her conversation, touching on topics like disinformation and diversity in clinical trials.

Alexander discusses the broader implications the case could have on FDA's ability to regulate the industry.

The move will bring Landos’ lead drug, NX-13, under AbbVie’s umbrella.

The shortage is due to a reported manufacturing interruption.

The drug was recently cleared to treat cardiovascular risks, making it eligible for Medicare Part D.

The agency released guidelines for vaccinations guidelines for children as young as 6 months old.

Cold Spring Harbor Laboratory details how the new tool will help reduce common barriers to trial participation.

Valder Curran discusses recent developments with the IRA.

The technology platform won the award for its work using AI to improve precision medicine.

The company will see the completion of its projects about a year earlier than expected.

The acquisition will bolster AstraZeneca’s ability to develop radioconjugates for cancer treatments.

The company’s software will be used to help with chest and breast cancer screenings.

The technology was used to develop new peptides.

The therapies are still in the early stages of development, but researchers are optimistic about the results.

As part of the partnership, BeiGene will serve as a sponsor at LLS events.

The online retailer will be able to provide customers with a selection of migraine, obesity, and diabetes medications.

The study, out of Sweden, researched the impact of the use of medication and mortality rates for patients with ADHD.

The platform will allow for a more direct method of antibody optimization.

Cosgrove discusses how a recent study utilized a high-tech data platform to bring a new perspective on data to the researchers.

The voluntary recall was ordered due to potential silicon particulate exposure.

Sapirstein discusses the current conditions that are impacting investors’ view of the life sciences industry.

Classic views on leadership are sometimes still the most effective.

Ricciardi discusses how new treatments require much more specific patient groups in studies.

Tucker discusses the possibilities that non-hallucinogenic psychedelics bring to the sector.

The medical side of the market is growing while the commercial side seems to be struggling.

Anderson discusses how AI can be used to take data collected by different processes and bring it into a usable format.

The winner will receive $1 million and the chance to partner with a major industry leader.

Researchers are debating whether to still include protection for this strain in vaccines.

Chases discusses how traditional media platforms still coexist with digital platforms and how this impacts promotion.